Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 4/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CRHR1 | P34998 | 8/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4015953 | 0.97 | PAK1 (0.56) | PAK1DRD4P2RX7MEN1KMT2A | |
| SCHEMBL4022745 | 0.92 | PAK1 (0.60) | PAK1DRD4P2RX7MEN1KMT2A | |
| SCHEMBL4024830 | 0.90 | PAK1 (0.56) | PAK1DRD4P2RX7MEN1KMT2A | |
| SCHEMBL4018426 | 0.87 | PAK1 (0.59) | PAK1P2RX7MEN1KMT2ACRHR1 | |
| SCHEMBL4024820 | 0.86 | DRD4 (0.48) | PAK1DRD4P2RX7MEN1KMT2A | |
| SCHEMBL4024809 | 0.85 | PAK1 (0.58) | PAK1DRD4P2RX7MEN1KMT2A | |
| SCHEMBL4020834 | 0.85 | PAK1 (0.60) | PAK1DRD4P2RX7MEN1KMT2A | |
| SCHEMBL4021914 | 0.83 | PAK1 (0.63) | PAK1DRD4P2RX7MEN1KMT2A | |
| SCHEMBL4019291 | 0.82 | PAK1 (0.63) | PAK1DRD4P2RX7MEN1KMT2A | |
| SCHEMBL4016278 | 0.82 | DRD4 (0.51) | PAK1DRD4P2RX7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066654-A1 | N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS | Bayer Schering Pharma AG (DE) | 2009-06-10 | — | — | EP | claimed |
| WO-2008028691-A1 | N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | claimed |